NEW YORK, June 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Trimble Navigation Limited (NASDAQ: TRMB), Giga-tronics Inc. (NASDAQ: GIGA), Garmin Ltd. (NASDAQ: GRMN), Sensata Technologies Holding NV (NYSE: ST) and Affymetrix Inc. (NASDAQ: AFFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3934-100free.
--
Trimble Navigation Limited Analyst Notes
On June 3, 2014, Trimble Navigation Limited (Trimble) announced its acquisition of the assets of MAYBIM, a privately-held company based in Provo, Utah. According to the Company, MAYBIM is a leader in providing 3D Building Information Modeling (BIM) services to contractors with a focus on mechanical, electrical and plumbing (MEP) contractors across the U.S. "Today's MEP contractors are increasingly receiving requests to use BIM on their projects, but the adoption and implementation takes time. The use of 3D BIM services to supplement their own capabilities can help MEP contractors accelerate that process," said Pat Bohle, General Manager of Trimble's MEP Division. "By combining the experience of the MAYBIM and the Trimble MEP BIM services team, we are able to expand our skills and capacity to support our client base's BIM capabilities through the full workflow including field layout and 3D laser scanning." The full analyst notes on Trimble are available to download free of charge at:
http://www.analystsreview.com/Jun-20-2014/TRMB/report.pdf
--
Giga-tronics Inc. Analyst Notes
On June 17, 2014, Giga-tronics Inc. (Giga-tronics) announced that it has received a new order from the Naval Air Warfare Center in Pawtuxet River, MD. The Company stated that the order is valued at approximately $2.4 million and is associated with its Model 8003 Precision Scalar Analyzer. John Regazzi, President and CEO of Giga-tronics, said, "We are committed to supporting the U.S. Navy's requirement for high accuracy device calibration and are pleased to be selected as a supplier of critical equipment for their metrology labs." The Company stated that it expects shipping the equipment to the Navy over the next six months. The full analyst notes on Giga-tronics are available to download free of charge at:
http://www.analystsreview.com/Jun-20-2014/GIGA/report.pdf
--
Garmin Ltd. Analyst Notes
On June 6, 2014, Garmin Ltd. (Garmin) announced the approval from the shareholders in accordance with Swiss corporate law for a cash dividend in the amount of $1.92 per share. According to the Company, the dividend is payable in four installments each of $0.48 and payable on June 30, 2014, September 30, 2014, December 31, 2014 and March 31, 2015 with record dates of June 17, 2014, September 15, 2014, December 15, 2014 and March 16, 2015 respectively. The full analyst notes on Garmin are available to download free of charge at:
http://www.analystsreview.com/Jun-20-2014/GRMN/report.pdf
--
Sensata Technologies Holding NV Analyst Notes
On June 17, 2014, Sensata Technologies Holding N.V. (Sensata) stock increased by1.71% to end the day at $44.69. The Company's stock grew 1.75% over the past three trading days compared to the Dow Jones Industrial Average which rose 0.44% and to Standard & Poor's 500 which went up 0.62% during the same trading period. The full analyst notes on Sensata are available to download free of charge at:
http://www.analystsreview.com/Jun-20-2014/ST/report.pdf
--
Affymetrix Inc. Analyst Notes
On June 5, 2014, Affymetrix Inc. (Affymetrix), together with BioDiscovery, announced that it has launched Nexus Copy Number for Affymetrix - a new analysis software which is specifically designed for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan® Cytogenetics Suite and OncoScan® FFPE Assay Kit. "CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of our cancer portfolio," says Dr. Andy Last, Executive Vice President and Chief Operating Officer at Affymetrix. "Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays." The full analyst notes on Affymetrix are available to download free of charge at:
http://www.analystsreview.com/Jun-20-2014/AFFX/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
